The Column Group
Overview
The Column Group (TCG) is a venture ecosystem dedicated to fueling scientific innovation in the life sciences industry. TCG takes a novel approach to venture capital funding with an edge-to-edge investment model primarily focused on company formation but with the financial wherewithal for long-term private and public capital support. This model exists within an ecosystem of funds, each with a clear strategy and focus, and all with a mandate of maximizing success through collaborative action. TCG Platform funds, TCG Opportunity funds, TCG Labs-Soleil and TCG Crossover (TCGX) wield complementary approaches for deploying capital and work together to propel technology platforms, single assets and later-stage programs forward from inception through exit.
Investments
| Company | Date | Stage | Lead |
|---|---|---|---|
| TriGemX Bio | Oct 2026 | Early Funding | Lead |
| Circle Pharma | Sep 2026 | Series E | Lead |
| InduPro | Aug 2026 | Series B | Lead |
| Tortugas Neuroscience | Aug 2026 | Series A | Lead |
| Remix Therapeutics | Jun 2026 | Private Placement | Co-investor |
For institutional investors. Book with your work email.
Key People
Peter Svennilson
Managing Partner and Founder
David Goeddel
Managing Partner
Tim Kutzkey
Managing Partner
Arnav Mehta
Venture Partner
Badreddin Edris
Venture Partner
Brian Wong
Venture Partner
John Josey
Venture Partner
Carla Daniel
Partner & Chief People Officer
Jeff Goater
Partner
Larry Lasky
Partner
Sarah Hymowitz
Partner
Michael Rape
iPartner
For institutional investors. Book with your work email.
Sector & Stage Mix
Industry, funding stage, and valuation band breakdowns.
FAQ
Where is The Column Group based?
The Column Group is headquartered in San Francisco, California, United States.
When was The Column Group founded?
The Column Group was founded in 2006.
How many portfolio companies does The Column Group have?
The Column Group has 33 portfolio companies in Caplight's dataset.
What are some companies in The Column Group's portfolio?
Recent investments visible on Caplight include TriGemX Bio, Circle Pharma, InduPro, Tortugas Neuroscience, Remix Therapeutics.
What was The Column Group's most recent investment?
The Column Group's most recent investment on Caplight was in TriGemX Bio in 2026.
What sectors does The Column Group focus on?
The Column Group focuses on Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Consumer & Commerce, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Healthcare & Life Sciences, Consumer & Commerce, Cybersecurity, Enterprise Software, FinTech.
What company stages does The Column Group focus on?
The Column Group typically invests at the MultiStage stage.
What is The Column Group's AUM?
The Column Group's assets under management are estimated between $1.0B and $10.0B.